NASDAQ:ONCY Oncolytics Biotech (ONCY) Stock Price, News & Analysis $0.41 +0.03 (+7.81%) Closing price 04:00 PM EasternExtended Trading$0.41 +0.00 (+0.58%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Oncolytics Biotech Stock (NASDAQ:ONCY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oncolytics Biotech alerts:Sign Up Key Stats Today's Range$0.37▼$0.4250-Day Range$0.38▼$0.8852-Week Range$0.37▼$1.30Volume1.49 million shsAverage Volume1.26 million shsMarket Capitalization$53.97 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing immunotherapies for cancer. The company’s lead product candidate is pelareorep, an investigational, intravenously delivered reovirus designed to selectively infect and destroy certain tumor cells while stimulating an immune response against cancer. Oncolytics is evaluating pelareorep in combination with other cancer treatments, including chemotherapy, hormonal therapies and immune checkpoint inhibitors. Its research has focused primarily on breast cancer and gastrointestinal cancers, including pancreatic cancer, with development programs intended to assess the therapy’s potential across multiple tumor types. Founded in 1998, Oncolytics Biotech is headquartered in Calgary, Alberta, and conducts clinical and corporate activities in North America and other regions through its research and development programs. The company is led by President and Chief Executive Officer Matt Coffey, Ph.D. Its common shares trade on the Nasdaq Capital Market under the symbol ONCY and on the Toronto Stock Exchange under the symbol ONC.AI Generated. May Contain Errors. Read More Oncolytics Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreONCY MarketRank™: 2.142763759965 of 5 starsOncolytics Biotech scored higher than 43% of companies evaluated by MarketBeat, and ranked 634th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingOncolytics Biotech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialOncolytics Biotech has a consensus price target of $5.00, representing about 1,114.8% upside from its current price of $0.41.Amount of Analyst CoverageOncolytics Biotech has only been the subject of 2 research reports in the past 90 days.Read more about Oncolytics Biotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Oncolytics Biotech are expected to grow in the coming year, from ($0.29) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Oncolytics Biotech's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.94% of the float of Oncolytics Biotech has been sold short.Short Interest Ratio / Days to CoverOncolytics Biotech has a short interest ratio ("days to cover") of 9.91.Change versus previous monthShort interest in Oncolytics Biotech has recently decreased by 3.83%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOncolytics Biotech does not currently pay a dividend.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.41 News SentimentOncolytics Biotech has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Oncolytics Biotech this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for ONCY on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows9 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders4.68% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by Institutions6.82% of the stock of Oncolytics Biotech is held by institutions.Read more about Oncolytics Biotech's insider trading history. Receive ONCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONCY Stock News HeadlinesOncolytics signs LOQTORZI supply deal for planned anal cancer study2 hours ago | msn.comOncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma3 hours ago | globenewswire.comGOP wipeout … but here's WORSE news for the marketA 3 trillion dollar crisis may be building beneath the surface of the stock market, retirement accounts, pensions, and even banks. Reuters reports alarm bells echoing 2007 subprime warnings, and bestselling author Dr. Martin Weiss says this one may already be underway. His free briefing outlines five steps investors are considering to help protect their portfolios.November 11 at 1:00 AM | Weiss Ratings (Ad)Oncolytics Biotech (ONCY) Projected to Post Earnings on WednesdayNovember 10 at 2:41 AM | americanbankingnews.comPelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma PatientsNovember 9 at 9:30 AM | globenewswire.comTranslational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven CancersNovember 4, 2026 | globenewswire.comOncolytics Biotech Reports Durable Responses in GOBLET Cohort 4 Anal Cancer Study and Advances Pelareorep Toward Registration October 27, 2026 | quiverquant.comQOncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven CancersOctober 27, 2026 | globenewswire.comSee More Headlines ONCY Stock Analysis - Frequently Asked Questions How have ONCY shares performed this year? Oncolytics Biotech's stock was trading at $0.8740 at the beginning of the year. Since then, ONCY stock has decreased by 52.9% and is now trading at $0.4116. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech Inc. (NASDAQ:ONCY) announced its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.03. Who are Oncolytics Biotech's major shareholders? Oncolytics Biotech's top institutional shareholders include International Assets Investment Management LLC (0.35%) and Fifth Third Bancorp (0.07%). Insiders that own company stock include Bernd R Seizinger, Wayne Pisano, Kirk Look, Thomas Charles Heineman, Allison Hagerman, Jared Kelly, Deborah Margaret Brown, Patricia S Andrews, Andrew Aromando and James T Parsons. View institutional ownership trends. How do I buy shares of Oncolytics Biotech? Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include NVIDIA (NVDA), NIO (NIO), Plug Power (PLUG), Sorrento Therapeutics (SRNE), Palantir Technologies (PLTR), Intel (INTC) and Nokia (NOK). Company Calendar Last Earnings8/12/2026Today11/11/2026Next Earnings (Estimated)11/11/2026AGM 202611/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ONCY's financial health is in the Red zone, according to TradeSmith. ONCY has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ONCY CIK1129928 Webwww.oncolyticsbiotech.com Phone(403) 670-7377Fax403-283-0858Employees29Year Founded1998Price Target and Rating Average Price Target for Oncolytics Biotech$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+1,114.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.76 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-442.99% Debt Debt-to-Equity RatioN/A Current Ratio1.35 Quick Ratio1.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-10.29Miscellaneous Outstanding Shares131,121,000Free Float124,985,000Market Cap$53.97 million OptionableNot Optionable Beta1.26 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:ONCY) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
